Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: January Update

Performance overview
Value at beginning of month: $139,073.53
Value at end of month: $161,832.17
Month over month change: 16.36%
Total IRR: 56.36%

Related indices, monthly change
NASDAQ: +8.73%
IVV (iShares Core S&P 500): +7.37%
IBB (iShares NASDAQ Biotechnology Index): +10.56%
MXI (iShares Global Materials): +7.19%
VEGI (iShares MSCI Global Agriculture Producers): +5.59%
ICLN (iShares Clean Energy): +2.90%

Individual performances


The announcement by Celgene of a Juno acquisition almost doubled their share price and biotechnology stocks had a strong month in general, which was reflected in the performance of the medical companies of the CSSBI. Other than those, chemicals companies Amyris and Global Bioenergies both had a strong start to the year. Will this be the year that chemicals synthetic biology companies make their business model work? We will see. Overall, January was another great month for the index, as it continues to outpace the general market.

Changes made to index

No changes to the index this month.

You can view the index here.

Allocation as of January 26, 2018


Calvin Schmidt Synthetic Biology Index: February Update

Calvin Schmidt Synthetic Biology Index: 2017 Review